Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Chia

Showing results (41-50 of 104) with videos related to

Pageof 11
Sort By:
NPJ Breast Cancer|February 13, 2021
Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapiesJohn F R Robertson, Angelo Di Leo, Stephen Johnston, et al.
Canadian Journal of Public Health = Revue Canadienne De Sante Publique|February 18, 2012
Effect of community population size on breast cancer screening, stage distribution, treatment use and outcomesRobert A Olson, Alan Nichol, Nadine R Caron, et al.
Breast Cancer Research and Treatment|November 2, 2011
Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 TrialKathleen I Pritchard, Alison Munro, Frances P O'Malley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 13, 2008
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancersStephen Chia, Brian Norris, Caroline Speers, et al.
The Oncologist|August 18, 2019
A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229)Stephen Chia, Phillipe L Bedard, John Hilton, et al.
The Oncologist|April 28, 2021
Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast CancerStuart Turner, Stephen Chia, Hemanth Kanakamedala, et al.
Current Oncology (Toronto, Ont.)|April 26, 2024
The Canadian Breast Cancer Symposium 2023 Meeting ReportTulin Cil, Jean-François Boileau, Stephen Chia, et al.
Breast (Edinburgh, Scotland)|March 28, 2025
Systematic literature review and trial-level meta-analysis of aromatase inhibitors vs tamoxifen in patients with HR+/HER2- early breast cancerWolfgang Janni, Michael Untch, Nadia Harbeck, et al.
Breast Cancer Research and Treatment|June 25, 2009
Predicting benefit from fulvestrant in pretreated metastatic breast cancer patientsOrit Freedman, Eitan Amir, George Dranitsaris, et al.
Clinical Breast Cancer|August 8, 2009
A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkersRinat Yerushalmi, Malcolm M Hayes, Karen A Gelmon, et al.
Pageof 11

Showing results (41-50 of 104) with videos related to

Sort By:
Pageof 11
NPJ Breast Cancer|February 13, 2021
Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapiesJohn F R Robertson, Angelo Di Leo, Stephen Johnston, et al.
Canadian Journal of Public Health = Revue Canadienne De Sante Publique|February 18, 2012
Effect of community population size on breast cancer screening, stage distribution, treatment use and outcomesRobert A Olson, Alan Nichol, Nadine R Caron, et al.
Breast Cancer Research and Treatment|November 2, 2011
Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 TrialKathleen I Pritchard, Alison Munro, Frances P O'Malley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 13, 2008
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancersStephen Chia, Brian Norris, Caroline Speers, et al.
The Oncologist|August 18, 2019
A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229)Stephen Chia, Phillipe L Bedard, John Hilton, et al.
The Oncologist|April 28, 2021
Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast CancerStuart Turner, Stephen Chia, Hemanth Kanakamedala, et al.
Current Oncology (Toronto, Ont.)|April 26, 2024
The Canadian Breast Cancer Symposium 2023 Meeting ReportTulin Cil, Jean-François Boileau, Stephen Chia, et al.
Breast (Edinburgh, Scotland)|March 28, 2025
Systematic literature review and trial-level meta-analysis of aromatase inhibitors vs tamoxifen in patients with HR+/HER2- early breast cancerWolfgang Janni, Michael Untch, Nadia Harbeck, et al.
Breast Cancer Research and Treatment|June 25, 2009
Predicting benefit from fulvestrant in pretreated metastatic breast cancer patientsOrit Freedman, Eitan Amir, George Dranitsaris, et al.
Clinical Breast Cancer|August 8, 2009
A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkersRinat Yerushalmi, Malcolm M Hayes, Karen A Gelmon, et al.
Pageof 11